UPDATE -- Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe PHILADELPHIA, May 24, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based...

Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe PHILADELPHIA, May 23, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based...

Hemispherx Biopharma Reviews Ampligen® Data With National Institute of Neurological Disorders and Stroke (NINDS) PHILADELPHIA, March 10, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced that the strong commitment by the National Institutes of Health (NIH)...

Hemispherx Biopharma Reminder Regarding Stockholder Open House at Manufacturing and Research Facility in New Jersey PHILADELPHIA, Aug. 19, 2015 (GLOBE NEWSWIRE) -- As previously announced and provided in the proxy materials, the Management and the Board of Directors of Hemispherx Biopharma (NYSE MKT:HEB) will host...

Hemispherx Enters Into an Agreement With myTomorrows for an Early Access Program for Rintatolimod in Europe PHILADELPHIA, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has executed an agreement with Impatients, N.V., a...